1 / 6

Oral Mucositis Therapeutics Pipeline to Witness Many Technological Advancements in the Coming Years

Oral Mucositis Therapeutics Pipeline Report Provides a Comprehensive Understanding of the Pipeline Activities Covering All Drug Candidates Under Various Stages of Development.

NidhiNehani
Télécharger la présentation

Oral Mucositis Therapeutics Pipeline to Witness Many Technological Advancements in the Coming Years

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Oral Mucositis Therapeutics Pipeline to Receive More Drug Designations from the USFDA in the Coming Years

  2. Oral Mucositis Therapeutics According to a new research report “Oral Mucositis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Oral Mucositis currently exhibits a pipeline with 18 drug candidates. Access Report Overview: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis Oral Mucositis therapeutics pipeline in 2017 The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug candidates in different stages of development. Oral mucositis is the most common complication of chemotherapy in cancer patients. It causes damage to mucosal lining of the mouth which results in formation of ulcers. It can result in several problems that includes severe pain in mouth, nutritional problems as a result of inability to eat and increased risk of infection due to open sores in the mucosa.

  3. Oral Mucositis Therapeutics ActoBiotics technology platform for Oral Mucositis drug development Oragenics, Inc. is using ActoBiotics technology platform for the development of their drug candidates for the treatment of oral mucositis. The technology platform produces a new class of orally delivered biopharmaceuticals. Through ActoBiotics technology platform, food-grade microbes are engineered to generate biologically contained ActoBiotics therapeutics for in situ expression and secretion of novel proteins and peptides including cytokines, enzymes, hormones and monoclonal antibodies within the body.

  4. Oral Mucositis Therapeutics Various Companies in the pipeline received Designations from the USFDA for the development of Oral Mucositis Therapeutics Pipeline The research also found that various companies received designations from the USFDA for the development of the drugs in the oral mucositis therapeutics pipeline. In November 2016, USFDA granted Fast Track designation to AG013 for the treatment of oral mucositis. Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc. and others.

  5. Oral Mucositis Therapeutics Download report sample at: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related